Watch live: Trump signs executive order to reschedule marijuana

President Trump signed an executive order from the Oval Office to move marijuana into a lower federal drug classification (aiming for Schedule III), a step short of full legalization. The action continues a rescheduling process initiated by the Biden administration in 2024 that was not completed, and may alter regulatory and commercial dynamics for the medical/recreational cannabis industry even as federal legalization remains off the table.

Analysis

Market structure: Rescheduling to Schedule III immediately benefits licensed multi-state operators (MSOs), ancillary service providers (payments, REITs) and pharma players with cannabinoid drugs by lowering federal risk and unlocking research/insurance pathways. Expect branded MSOs (Curaleaf, Green Thumb) and real estate plays (IIPR) to gain pricing power while fragmented Canadian producers face margin compression; I estimate demand growth of ~15–30% nationwide over 12–36 months as medical prescribing and institutional buyers ramp.

Risk assessment: Key tail risks include judicial reversal or a narrowly written order that preserves major constraints (IRS 280E, interstate commerce), each with 10–25% probability of materially slowing adoption; DEA rulemaking and litigation are 60–180 day catalysts. Immediate days: elevated volatility and flows; short-term (weeks–months): credit spread tightening for high-yield MSO debt by 100–250 bps if banks re-engage; long-term (12–36 months): consolidation and margin normalization. Hidden dependency: banking/regulatory plumbing (FDIC/FinCEN guidance) and tax code (280E) still determine free cash flow more than scheduling alone.

Trade implications: Favor liquid, diversified exposure (MSOS ETF) and selective LEAPs on large-cap operators (TLRY, CGC) while avoiding small OTC growers with weak balance sheets. Use options to express asymmetric upside (12–18 month ATM to 25% OTM calls) and protect with defined-risk put spreads; expect implied vol mean-reversion post-rule within 2–6 weeks. Rotate modestly out of defensive alcohol beverage exposure into regulated cannabis retail/real estate over 3–12 months.

Contrarian angles: Market will under-price the friction from tax and banking rules — scheduling is necessary but not sufficient; the consensus bullish take ignores continued state licensing constraints and potential pharma competition. Historical parallel: Canada’s 2018 federal legalization produced strong rallies then a multi-year shakeout; expect a 30–60% dispersion in operator returns and frequent M&A opportunities rather than uniform winners.

Key Decisions for Investors

• Establish a 2–3% portfolio position in MSOS (ETF) within 5 trading days to capture diversified upside; set a trailing stop at -20% and consider trimming 40–60% of the position on a +50% move within 6–12 months.
• Initiate 1–2% long positions in liquid large-cap operators: TLRY (Tilray) and CGC (Canopy Growth) split 50/50; complement with 12–18 month LEAP calls (ATM to 25% OTM) sized at 0.5% notional each to cap downside and target 2x+ upside if DEA final rule is supportive.
• Add 1% long in Innovative Industrial Properties (IIPR) REIT as a play on property demand; use a 9–12 month covered-call strategy to generate yield if financing costs remain >5%.
• Open a pair trade: long 1.5% Green Thumb (GTBIF) / short 0.75% Aurora Cannabis (ACB) to express US MSO vs Canadian low-margin producer divergence; set stop-losses at -25% on each leg and review after DEA final rule (target review 60–180 days).
• Watch two binary catalysts before scaling: DEA final rule (expected 60–180 days) and any congressional/IRS action on 280E within 6–12 months; increase conviction and size if both outcomes favor banking access and 280E relief, reduce if either remains unresolved.